There was a mistake in Figures 1–3 as published. The figures were placed in the wrong order in the text. The corrected Figures 1–3 appears below.
Progression of syndecan-1.
Two box plot charts compare Syndecan-1 levels in nanograms per milliliter. The left red chart shows NMP 1, NMP 2, and NMP 3; NMP 2 and NMP 3 have higher median values and more outliers, with statistically significant differences marked by asterisks. The right blue chart displays BL, ICU, D1, D2, and D3 groups; levels increase from BL to ICU and remain elevated for D1 to D3, each comparison marked as significant.
Progression of heparan sulfate.
Box plot comparing heparan sulfate levels in nanograms per milliliter across NMP 1-3 (red) and BL, ICU, D1, D2, D3 (blue) groups, with statistically significant differences between NMP and BL, and BL and D3, indicated by asterisks.
Syndecan-1 during NMP depending on the occurrence of EAD.
Box plot comparing Syndecan-1 concentrations (ng/mL) between No EAD (green) and EAD (orange) groups at three time points (NMP 1, NMP 2, NMP 3); EAD groups consistently show higher median levels, with significant differences indicated by asterisks above each pair.
There was a mistake in the caption of Figure 2 as published. The corrected caption of Figure 2 appears below.
There was a mistake in the caption of Figure 3 as published. The corrected caption of Figure 3 appears below.
There was a mistake in the caption of Figure 4 as published. The corrected caption of Figure 4 appears below.
Comparison of syndecan-1 during NMP between organs classified as transplantable and non-transplantable.
Box plot graphic compares Syndecan-1 levels in nanograms per milliliter between non-transplantable and transplantable groups at three NMP stages. Non-transplantable groups consistently show higher median and wider range values. Statistically significant differences are marked between non-transplantable and transplantable groups for NMP 1 and NMP 3, as indicated by asterisks and horizontal brackets.
A correction has been made to the section Results, Sub Section “Glycocalyx Damage Parameters during NMP”, Subsub Section “Heparan Sulfate”, Paragraph “1”. The Sentence: “No significant dynamics of heparan sulfate were observed during NMP (p = 0.100) (Figure 4)” has been changed to: “No significant dynamics of heparan sulfate were observed during NMP (p = 0.100) (Figure 2).”
A correction has been made to the section Section “Results”, Sub Section “Outcome Associations of Glycocalyx Injury During NMP”, Paragraph “1”. The Sentence: “Furthermore, perfusate syndecan-1 values where significantly higher in grafts of recipients who developed EAD (n = 10) compared to those without EAD (n = 11) (4,331.5 (4,180.3–5,033.7) ng/mL vs. 2,800.7 (2,480.5–3,618.7) ng/mL; p = 0.024 and 9,379.7 (6,181–104,923) ng/mL vs. 4,338.9 (3,730–6,201.3) ng/mL; p = 0.013 and 8,663.6 (6,926.2–11,551.9) ng/mL vs. 5,096.5 (3,795–5,679.5) ng/mL; p = 0.013) (Figure 2).” should be changed to: “Furthermore, perfusate syndecan-1 values where significantly higher in grafts of recipients who developed EAD (n = 10) compared to those without EAD (n = 11) (4,331.5 (4,180.3–5,033.7) ng/mL vs. 2,800.7 (2,480.5–3,618.7) ng/mL; p = 0.024 and 9,379.7 (6,181–104,923) ng/mL vs. 4,338.9 (3,730–6,201.3) ng/mL; p = 0.013 and 8,663.6 (6,926.2–11,551.9) ng/mL vs. 5,096.5 (3,795–5,679.5) ng/mL; p = 0.013) (Figure 3).”
A correction has been made to the section Section “Results”, Sub Section “Outcome Associations of Glycocalyx Injury During NMP”, Paragraph “2”. The Sentence: “Grafts that were classified as transplantable (n = 23) exhibited significantly lower syndecan-1 levels at the onset of perfusion (3,892.6 (2,883.7–4,561.2) ng/mL) and after six hours of perfusion (5,915.7 (4,082.2–9,379.7) ng/mL) when compared to grafts that were classified as unsuitable for transplantation due to their metabolic profile (5,653.7 (5,074–11,706.6) ng/mL; p = 0.001 and 7,764.8 (7,133.6–12,740.7) ng/mL; p = 0.037) (Figure 3).” should be changed to “Grafts that were classified as transplantable (n = 23) exhibited significantly lower syndecan-1 levels at the onset of perfusion (3,892.6 (2,883.7–4,561.2) ng/mL) and after six hours of perfusion (5,915.7 (4,082.2–9,379.7) ng/mL) when compared to grafts that were classified as unsuitable for transplantation due to their metabolic profile (5,653.7 (5,074–11,706.6) ng/mL; p = 0.001 and 7,764.8 (7,133.6–12,740.7) ng/mL; p = 0.037) (Figure 4).”
A correction has been made to the section Section “Results”, Sub Section “Glycocalyx Damage Parameters in the Recipient”, Paragraph “2”. The Sentence: “However, from postoperative day 1 to postoperative day 2 (24.3 (13.2–35.1) ng/mL; p = 0.006) and postoperative day 3 (18.7 (10.1–30.8) ng/mL; p = 0.008), heparan sulfate levels experienced a decrease, reaching values below the preoperative baseline (p = 0.006) (Figure 4).” should be changed to “However, from postoperative day 1 to postoperative day 2 (24.3 (13.2–35.1) ng/mL; p = 0.006) and postoperative day 3 (18.7 (10.1–30.8) ng/mL; p = 0.008), heparan sulfate levels experienced a decrease, reaching values below the preoperative baseline (p = 0.006) (Figure 2).”
The original article has been updated.
Generative AI statement
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.